Sanofi Launches Insulin-Compatible GLP1 Receptor Agonist Lyxumia In Japan
This article was originally published in PharmAsia News
Executive Summary
Sanofi has launched Lyxumia subcutaneous injection (lixisenatide), the only GLP-1 receptor agonist that can be used in combination with insulin, for the treatment of type 2 diabetes in Japan.